CD4 and neoplasm: As these cells express MHC class II molecules, it is most likely that both resident macrophages and microglial cells participate to the tumor antigen presenting function necessary to stimulate tumor specific CD4 + T cells, thus triggering the adaptive immune response leading to GBM rejection.